Tecentriq + chemo increase OS, PFS in untreated extensive stage small cell lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login